Arrowhead reports 73% average CSF tau reduction in early Alzheimer’s drug trial
Arrowhead Pharmaceuticals disclosed interim Phase 1/2a data for its RNAi therapeutic ARO‑MAPT, showing a mean 73% reduction in cerebrospinal‑fluid total tau at Day 105 in healthy volunteers, with a maximum individual drop of 85% after a 12.8 mg/kg dose. The drug was generally well tolerated, with only mild adverse events and no serious safety issues. The company will discuss additional results in a webinar and continues enrollment in early Alzheimer’s cohorts, with further data expected in 2027.
Why it matters
The data triggered a pre‑market rally in Arrowhead stock, which rose 8.4% to $63 from $58.13, reflecting investor optimism about the platform’s first‑ever clinical validation for crossing the blood‑brain barrier. The price move may affect short‑term trading and valuation models that incorporate clinical milestones.
Key facts
- 1Mean cerebrospinal‑fluid total tau reduction of 73% at Day 105 in healthy volunteers. stocktitan.net
- 2Maximum individual tau reduction of 85% at Day 105. stocktitan.net
- 3Highest tested dose was 12.8 mg/kg administered on Days 1 and 15. stocktitan.net
- 4No serious adverse events, deaths, or treatment discontinuations were reported. stocktitan.net
- 5Arrowhead stock rose 8.4% in pre‑market trading, trading at $63 versus a prior close of $58.13. investing.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.